Effect of Probiotics on Appetite Regulation in Adults With Overweight/Obesity
Key facts
- Where
- Maastricht, NetherlandsSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 20 and 70 years old?
Source: NCT07715955, who can take part
Where in Netherlands
- Maastricht University, Department of Nutrition and Movement SciencesMaastricht, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Maastricht University Medical Center
- Trial code
- NCT07715955
- Record updated
- 12 August 2026
- Original description
The goal of this 16-week randomised, placebo-controlled parallel study is to investigate the effect of a newly formed probiotic supplement on satiety and gut microbiota composition in healthy men and women with overweight or obesity form 20-70 years old. The main question it aims to answer is:Read full original descriptionShow less
Probiotic Regulation of Food Intake Through Satiety Stimulation and Gut Microbiota Modulation
The goal of this 16-week randomised, placebo-controlled parallel study is to investigate the effect of a newly formed probiotic supplement on satiety and gut microbiota composition in healthy men and women with overweight or obesity form 20-70 years old. The main question it aims to answer is:
Does the probiotic supplement increase feelings of satiety and alter gut microbiota composition?
Participants will:
* Receive a daily dose of 6 g probiotic supplement (packed in sachets of 3 g) or placebo for 16 weeks. * Visit the research unit 3 times at baseline, week 8 and week 16 of the intervention for blood draws and delivering fecal samples. * Keep a study diary to report deviations from their daily habits and fill in food questionnaires.
Inclusion: Men and women, aged between 20-70 years; BMI ³ 25 kg/m2; Stable body weight (weight gain or loss < 3 kg in the past three months); Willingness to give up being a blood donor from 8 weeks before the start of the study, during the study and for 4 weeks after completion of the study; No difficult venipuncture as evidenced during the screening visit.
Exclusion: Abuse of drugs; Use of products or dietary supplements known to interfere with the main outcomes 3 months prior to the start of the study as judged by the principal investigators; Use of an investigational product within another biomedical intervention trial within the previous 1-month; use of antibiotics up to 3 months prior to the study; Gastrointestinal disease (including IBD and IBS); Severe medical conditions that might interfere with the study, such as epilepsy, asthma, kidney failure or renal insufficiency, chronic obstructive pulmonary disease, autoimmune disease and rheumatoid arthritis; Active cardiovascular disease like congestive heart failure or cardiovascular event, such as an acute myocardial infarction or cerebrovascular accident; Psychiatric diagnoses including clinical depression; use of lipid- and glucose lowering medication, corticosteroid use; Diabetic patients (type 1 and type 2); More than 2 units alcoholic consumptions per day for women and 3 for men; Intolerances or dietary habits that might interfere with the study (i.e. lactose intolerance or veganism); pregnancy; smoking, vaping.